Last reviewed · How we verify
Tocilizumab(400mg)
Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting IL-6 signaling and reducing inflammatory cytokine production.
Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting IL-6 signaling and reducing inflammatory cytokine production. Used for Rheumatoid arthritis, Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.
At a glance
| Generic name | Tocilizumab(400mg) |
|---|---|
| Also known as | control group |
| Sponsor | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University |
| Drug class | IL-6 receptor antagonist (monoclonal antibody) |
| Target | IL-6 receptor (IL-6R) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Tocilizumab binds to both soluble and membrane-bound IL-6 receptors, preventing IL-6 from activating immune cells and triggering the inflammatory cascade. This mechanism suppresses systemic inflammation and is particularly effective in conditions driven by IL-6-mediated pathology, such as rheumatoid arthritis and cytokine release syndrome.
Approved indications
- Rheumatoid arthritis
- Giant cell arteritis
- Polyarticular juvenile idiopathic arthritis
- Systemic sclerosis-associated interstitial lung disease
- Cytokine release syndrome (including CAR-T cell-induced)
Common side effects
- Infection (including serious infections)
- Elevated liver enzymes (ALT/AST)
- Hyperlipidemia
- Neutropenia
- Gastrointestinal perforation
- Headache
Key clinical trials
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study (PHASE2)
- Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19 (PHASE2)
- A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 (PHASE2)
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: